StemCyte’s REGENECYTE Prepares for Phase III Trials Following FDA Endorsement for Long COVID Therapy
StemCyte’s cord blood therapy REGENECYTE is progressing to Phase III trials for long COVID, with FDA feedback supporting a streamlined trial design and early compassionate use in the U.S.
